Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Post by steadfaston May 20, 2022 9:16am
288 Views
Post# 34697850

SVA POTENTIAL TO HAVE $96 Million in Cash

SVA POTENTIAL TO HAVE $96 Million in CashWarrants:
25M in Aug & Sept       $ 8M  at 30-35 cents, a for sure  deal
20M March @ 1.70        34M  accelerate upon $3.05 per share
Evotec                          27M
Cash as at Jan 31          27M
Total                            $96M
That should get the attention of Big Pharma + Analysts recommending SVA, all
with targets over $3.00.  We have the most beautiful Chart with a Fibonacci screaming
for a weekly close over $1.60 so the stock can reach next target of Minimum $3.75,
and ideally it should go to the 1.618 extension which is all the way up to $5.50.

The Scientists have performed - now it is time for the I.R. guys to perform, they have
been given a gift on a silver platter - if they don't soon get this stock on a weekly close
above $1.60 - Big Pharma will take us out for a song.    The iPSC DEAL should be
worth another $1B to SVA and our stock sits at $1.46.   SOMETHING IS WRONG.
Don;t take my word, look at the Chart, ask your buddies who participate in Fibonacci.


<< Previous
Bullboard Posts
Next >>